Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need
The WHO recognizes human African trypanosomiasis, Chagas disease and the
leishmaniases as neglected tropical diseases. These diseases are caused by parasitic …
leishmaniases as neglected tropical diseases. These diseases are caused by parasitic …
An overview on target-based drug design against kinetoplastid protozoan infections: Human African trypanosomiasis, Chagas disease and leishmaniases
V Kourbeli, E Chontzopoulou, K Moschovou, D Pavlos… - Molecules, 2021 - mdpi.com
The protozoan diseases Human African Trypanosomiasis (HAT), Chagas disease (CD), and
leishmaniases span worldwide and therefore their impact is a universal concern. The …
leishmaniases span worldwide and therefore their impact is a universal concern. The …
Protease inhibitors targeting coronavirus and filovirus entry
Y Zhou, P Vedantham, K Lu, J Agudelo, R Carrion Jr… - Antiviral research, 2015 - Elsevier
In order to gain entry into cells, diverse viruses, including Ebola virus, SARS-coronavirus
and the emerging MERS-coronavirus, depend on activation of their envelope glycoproteins …
and the emerging MERS-coronavirus, depend on activation of their envelope glycoproteins …
Current drug therapy and pharmaceutical challenges for Chagas disease
One of the most significant health problems in the American continent in terms of human
health, and socioeconomic impact is Chagas disease, caused by the protozoan parasite …
health, and socioeconomic impact is Chagas disease, caused by the protozoan parasite …
SARS-CoV-2 entry inhibitors: small molecules and peptides targeting virus or host cells
The pandemic evolution of SARS-CoV-2 infection is forcing the scientific community to
unprecedented efforts to explore all possible approaches against COVID-19. In this context …
unprecedented efforts to explore all possible approaches against COVID-19. In this context …
Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: a review
Chagas disease, leishmaniasis and schistosomiasis are neglected diseases (NDs) and are
a considerable global challenge. Despite the huge number of people infected, NDs do not …
a considerable global challenge. Despite the huge number of people infected, NDs do not …
Advances in preclinical approaches to Chagas disease drug discovery
F Villalta, G Rachakonda - Expert opinion on drug discovery, 2019 - Taylor & Francis
ABSTRACT Introduction: Chagas disease affects 8–10 million people worldwide, mainly in
Latin America. The current therapy for Chagas disease is limited to nifurtimox and …
Latin America. The current therapy for Chagas disease is limited to nifurtimox and …
Anthelmintic drug discovery: into the future
TG Geary, JA Sakanari… - The Journal of …, 2015 - meridian.allenpress.com
The last half-century has provided all of the (few) drugs currently used to treat human
helminthiases. Concern regarding the long-term utility of these drugs, given how readily …
helminthiases. Concern regarding the long-term utility of these drugs, given how readily …
Vinyl sulfone-based peptidomimetics as anti-trypanosomal agents: design, synthesis, biological and computational evaluation
E Dunny, W Doherty, P Evans… - Journal of Medicinal …, 2013 - ACS Publications
A series of vinyl sulfone-containing peptidomimetics were rationally designed, synthesized,
and evaluated against Trypanosoma brucei brucei. These electrophilic compounds are …
and evaluated against Trypanosoma brucei brucei. These electrophilic compounds are …
Drug strategies targeting CYP51 in neglected tropical diseases
JY Choi, LM Podust, WR Roush - Chemical Reviews, 2014 - ACS Publications
CYP51 is considered one of the most ancient P450 protein families. 1 It is perhaps the only
P450 protein family whose members are spread across all biological kingdoms, although it …
P450 protein family whose members are spread across all biological kingdoms, although it …